The potential value of measurements of peripheral bone mass in rheumatoid arthritis (RA) as an assessment of long-term disease activity has recently received renewed attention. This study examines the effects of RA and corticosteroid therapy on newer methods of measuring peripheral bone mass, comparing the results with dual-energy X-ray absorptiometry (DXA) at axial sites. Peripheral quantitative computed tomography of the radius, ultrasound of the calcaneus, and DXA of the hip and spine were compared between 29 controls and 46 women with RA of whom 25 were receiving low-dose corticosteroid therapy. Bone mass was significantly reduced in the RA groups for: (i) radial trabecular (36.1%) and total (15.6%) measurement sites; (ii) calcaneal ultrasound attenuation (31.7%) and velocity (6.6%); and (iii) femoral neck (15.4%) bone mineral density. Lumbar spine and radial cortical measurements were not significantly affected. There were no significant differences between the RA groups. Disease activity and physical activity did appear to be responsible for much of the reduction in bone mass. These results demonstrate that RA is associated with significant bone loss at the hip, radius and calcaneus, but not at the lumbar spine. In this small study, low-dose corticosteroids had little additional deleterious effect.
R bone mass is a well-recognized feature of rheumatoid arthritis (RA), with many studies showing reductions at axial and appendicular sites [1] . The effect of oral corticosteroid therapy on bone mass in RA is contentious, especially at appendicular sites [2, 3] . There is evidence to support the concept of generalized bone loss [4, 5] , but controversy exists about the distribution and degree of bone loss, and the relative contribution of immobility, low-dose corticosteroids and the systemic effects of RA [3] [4] [5] [6] [7] [8] .
Peripheral quantitative computed tomography (pQCT) is a recently developed technique which allows independent quantification of trabecular and cortical bone at the ultra-distal radius in close proximity to the carpus. As the carpus is frequently involved in RA, and periarticular bone loss is a characteristic feature, pQCT seems an ideal technique to study periarticular bone changes related to RA. Additionally, trabecular bone is metabolically more active than cortical bone, and therefore more responsive to stimuli such as corticosteroid therapy [9] , which is used to treat a proportion of patients with RA. Accordingly, by quantifying trabecular bone, pQCT may be able to differentiate the effects of RA disease activity and corticosteroid therapy on bone at the radial site.
The ankle and subtalar joints are also frequently involved in RA. One might therefore expect the os calcis, which is also a trabecular-rich bone [10] , to be affected in a similar manner to the distal radius by local inflammatory processes and corticosteroid therapy. Calcaneal ultrasound is also thought to reflect bone architecture as well as density [11] , both of which are important determinants of bone strength [12] .
We have examined the relative importance of corticosteroids, disease parameters and lifestyle on bone mass in postmenopausal women with RA, using the newer techniques of pQCT and ultrasound, and compared the results with dual-energy X-ray absorptiometry (DXA) of hip and spine.
PATIENTS AND METHODS

Patient selection
Seventy-five ambulatory, Caucasian, postmenopausal women were enrolled into the study. Twentynine of the 75 were controls-volunteers selected to match the RA group from a previously studied random population who took part in an epidemiological study (European Vertebral Osteoporosis Study, EVOS) [13] . They were known to fulfil criteria for normality 2 yr before the current study and agreed to return for further assessment. The remaining 46 women had suffered from RA (as defined by the American College of Rheumatology) [14] for at least 6 months, and were recruited from out-patient clinics and a case note review. Twenty-five of the RA women had been on long-term low-dose prednisolone therapy (E10 g/ day) for at least 6 months (RA + P group). The remaining 21 had never received oral corticosteroids (RA group). Patients who had received intra-articular steroid were not excluded. Subjects with abnormal renal function (serum creatinine q140 mmol/l) or other Submitted 13 December 1995; revised version accepted 5 July 1996.
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= 1997 British Society for Rheumatology 43 conditions known to affect bone metabolism were excluded, as were individuals taking drugs such as hormone replacement therapy (HRT) and bisphosphonates. Patients on thiazide diuretics were not excluded. Each individual had all assessments performed on the same day. Informed consent was obtained and the study received local ethical committee approval.
Clinical data
Data collected included age, height, weight, years since menopause, smoking history (cigarettes/day) and alcohol consumption (units/week). Dietary calcium intake (mg/day) was determined by a locally derived questionnaire, and level of physical activity by the Framingham questionnaire. All individuals had a lateral thoracolumbar spine X-ray (T4-L5) viewed separately by two observers (JCM and RM) and fractures noted (defined as a reduction of 25% in anterior, mid or posterior vertebral body height).
RA patients completed a health assessment questionnaire (HAQ). Articular index (painful joint count only), mean grip strength of three measurements of right and left hands (mmHg), visual analogue pain score (150 mm horizontal line) and the time taken to walk 15 m on level ground were recorded. X-rays of hands and wrists were scored using the Larsen method by two separate observers (JCM and RM). Where there was disagreement, the X-rays were viewed together and a score agreed. Serum C-reactive protein and rheumatoid factor were measured using standard laboratory methods.
Bone density measurements
pQCT was performed at the ultra-distal radius of the non-dominant forearm using the Stratec XCT-960 scanner (Stratec Medizintechnik, Germany). The measurement scan occurs at a distance proximal to the ulna styloid process of 4% of the total ulnar length, and the following measurements are obtained: total (Qtot), trabecular (Qtrab) and cortical (Qcort) BMD. In vivo short-term precision, expressed as coefficient of variation (CV), in our hands is 1.24, 1.33 and 1.88%, respectively, in young normal healthy females [15] . Corresponding figures in postmenopausal females with RA are poorer: 1.6, 4 and 2.8% for Qtot, Qtrab and Qcort, respectively (unpublished data based on paired measurements in eight of these study subjects carried out on the same day with their forearm being removed from the scanner between scans). pQCT was not possible in one RA subject due to bilateral wrist surgery.
Ultrasound of the non-dominant os calcis was performed using the McCue CUBA Clinical (McCue Ultrasound, Winchester). Broadband ultrasound attenuation (BUA) and velocity of sound (VOS) are recorded, the CVs in our centre being 3.8 and 1.38%, respectively (based on paired measurements in 16 normal individuals with the foot removed from the machine between measurements). Owing to machine servicing, ultrasound data are missing from seven controls and one RA subject.
DXA was performed using a single Norland XR26-Mark II bone densitometer. Measurements were made at the left femoral neck (FN) and lumbar spine [(LS): L2-4] using an anterior-posterior view. Fractured vertebrae were excluded from the analysis. The CVs are 0.9 and 2.8% for LS and FN, respectively [16] . FN measurement was not possible on one RA + P subject due to bilateral hip replacements.
Statistical analysis
Results for continuous variables were expressed as the mean with .. if the data were normally distributed, otherwise as the median with ranges. Categorical data were examined using the x 2 test. Variables common to all three groups were compared using the one-way analysis of variance (ANOVA) or Kruskal-Wallis where appropriate. Subsequent comparisons among groups were performed through the use of Scheffe´'s multiple comparison test. Variables relevant only to the RA groups were compared using the unpaired t-test or Mann-Whitney U-test. Bone measurements across groups were examined having corrected for the influence of age, height, weight and years postmenopause by analysis of covariance with subsequent multiple comparison testing among groups. The independent relationships between corticosteroid use, RA variables, lifestyle variables and bone mass measurements were examined using Pearson correlation coefficients and stepwise multiple regression analysis. The level of statistical significance is taken as 0.05.
RESULTS
Detailed clinical data for the three groups are given in Table I . There were no significant differences in age, years postmenopause, height, weight, smoking habit or dietary calcium among groups, although the RA + P group was slightly heavier and more years postmenopause than the others. A greater proportion of the control group consumed alcohol than either RA group, although the amount consumed was not significantly different (P = 0.16; Kruskal-Wallis). The physical activity index was significantly higher in the control group compared to either RA group, but not significantly different between RA groups. Thiazide diuretic use was similar for the combined RA groups and control group. Seventeen (81%) of the RA group and 19 (76%) of the RA + P group were taking disease-modifying agents (sulphasalazine, auranofin, hydroxychloroquine, penicillamine, myocrisin, methotrexate or azathioprine). The median disease duration was 4 yr greater in the RA + P group (P = 0.24; Mann-Whitney U-test) and although there was a trend toward worse disease parameters in the RA + P group, significance was reached only for the HAQ. There were more vertebral fractures in the RA groups than controls, although the difference was not significant.
Bone mass measurements are detailed in Table II . There were significant reductions in both RA groups compared to the control group for all measurements Categorical variables compared by x 2 test ( §Fisher exact x 2 test after compression of (RA) and (RA + P) groups into a single group).
except the LS and forearm cortical BMD after adjustment for the influence of age, height, weight and years postmenopause. There were no significant differences between the RA groups for any bone mass measurement. Combining the RA groups, the percentage difference in bone mass compared to controls was −36.1, −15.6 and +2.4% for the forearm trabecular, total and cortical measurements, respectively, −31.7 and −6.6% at the os calcis for BUA and VOS, respectively, and −15.4% at the FN and −6.7% at the LS.
Stepwise multiple linear regression analyses on the whole population showed that weight and physical activity (PAQ) were positively correlated to LS bone mineral density (BMD) Table III shows the correlations of individual RA disease variables with pQCT and ultrasound measurements for the combined RA groups. The Larsen score for the non-dominant wrist and whole hand (wrist + MCPs + PIPs) was negatively correlated with Qtrab, BUA and VOS, whilst the Larsen score of the non-dominant wrist was positively correlated with Qcort. Rheumatoid factor titre was negatively correlated with Qtrab, BUA and VOS, whilst grip strength was positively correlated with Qtrab and BUA.
DISCUSSION
This study has demonstrated marked reductions in appendicular bone mass measurements in patients with RA using novel bone mass measurement tools. Some appendicular measurement changes were more marked than those noted at the FN and LS, with the changes at the latter site being insignificant in this small study.
pQCT measurements were difficult in a small number of patients with RA, and the precision of pQCT is poorer in this population. There are several reasons for this. Firstly, the mean BMD values are considerably lower than those found in young normal females due to age differences and the effects of RA. As the CV is a function of the error and mean of the measurements, lower mean BMD values will result in higher CVs and apparently poorer precision. Trabecular BMD, being much lower, results in a considerably higher CV. Secondly, visualization of the radiocarpal joint is important in accurate positioning of the scanner for baseline scans and repositioning in follow-up scans. In patients with more severe RA, where the normal anatomical landmarks are distorted, accurate positioning can be difficult. In such cases, measurement occurs at the most distal point where the radius and ulna can be visually separated. Repositioning can be aided by the use of scan voxel numbers, which can be used as a surrogate marker of the cross-sectional area, and therefore position of the measurement site [15] . Unless there is severe destruction and resorption of the distal radius and ulnar, measurement scans in the RA population should be in a position similar to those of the control group. In this study, pQCT trabecular and total BMD measurements were markedly reduced in the RA groups (36.1 and 15.6%, respectively) compared with controls, with very little difference between the RA groups. These data are in keeping with previous studies examining radial bone loss in patients with non-steroid-treated RA using pQCT [17, 18] . There are, however, some important differences between the studies. The previous longitudinal studies examined premenopausal and postmenopausal females with early (Q3 yr) RA, whilst our cross-sectional study population is purely postmenopausal with longer and variable disease duration. The pQCT scanners used also differed. An 125 I rather than X-ray radiation source was used previously, trabecular BMD was measured at the 8-10% and cortical BMD at the distal 1/3 site (rather than the 4% site in our study). As the proportion of trabecular and cortical bone changes dramatically over short distances at the distal radius [19] , these are important differences. Nevertheless, annual rates of loss of up to 25% were recorded for trabecular BMD, whilst cortical BMD changes were similar to the control group [17] , results similar in distribution and magnitude to ours. Rapid trabecular bone loss at the radius occurs early in the disease process with subsequent slowing [18] . In view of the substantially lower trabecular BMD found in the RA groups, our data would suggest that there is considerable ongoing bone loss beyond this initial period of rapid loss, although this would be better addressed by a long-term longitudinal study. The strong correlation of whole hand and wrist Larsen scores with trabecular BMD suggests that local inflammatory mechanisms responsible for joint damage, and resultant wrist immobility, have important adverse effects on ultra-distal radial bone mass. An increasing rheumatoid factor titre was negatively correlated to trabecular bone, which may be related to more aggressive local disease in such individuals. The correlation of grip strength with trabecular BMD supports the concept that mechanical loading and stimulation have a beneficial effect on local bone mass [20] . In this case, it is detectable within the trabecular component, which being more metabolically active, is more responsive to such stimuli.
As corticosteroid-induced bone loss preferentially affects trabecular bone, one might expect pQCT to be a sensitive technique for detecting such an effect. However, it is apparent that there is no significant corticosteroid effect on any of the forearm BMD measurements, even within the trabecular component. This is almost certainly due to the juxta-articular, inflammatory-driven bone loss [21] overwhelming other mechanisms affecting trabecular bone at this site. The radial measurement site is therefore an important consideration. That for SPA is more proximal than pQCT, and as such is further removed from the inflammatory process occurring at the wrist. The effect of corticosteroid could therefore be more pronounced at a more proximal site, which might explain why some have found significantly lower radial bone mass in patients with corticosteroid-treated RA [2] . In keeping with our results, others found no significant corticosteroid effect at the radius [3] .
Similarly, immediate postmenopausal bone loss preferentially affects trabecular rather than cortical bone, yet the duration since menopause was negatively correlated with total and cortical, but not trabecular, BMD. Presumably, this is also due to the periarticular inflammatory process overwhelming menopausal effects on trabecular bone, but having much less effect upon cortical bone, which is metabolically less active. Cortical bone comprises 55% of the pQCT total BMD measurement which explains the relationship of duration since the menopause with the latter BMD. Cortical bone is also known to undergo postmenopausal as well as age-related change [22] .
There were no difficulties in performing ultrasound of the os calcis in our RA patients as the foot recess was wide enough to accommodate broad feet, and application of the transducers was not impaired by the degree of subtalar deformity. There were reductions in ultrasound attenuation and velocity of 31.7 and 6.6%, respectively, in the combined RA group, again with no additional significant steroid effect. Weight was an important determinant of ultrasound measurements, as was the Larsen index in the RA groups. The latter finding is particularly intriguing as the Larsen index was measured at the hand and wrist. This points towards active RA producing similar degrees of periarticular bone loss and erosion at the wrist and heel. The same inflammatory mechanisms causing bone loss at the wrist may well affect the trabecular-rich os calcis, explaining the correlation between the Larsen index at the wrist and the ultrasound measurements at the os calcis. As for radial trabecular BMD, and presumably for the same reason, both calcaneal ultrasound measurements were negatively correlated with a rising titre of rheumatoid factor. It is difficult to explain the correlation between grip strength and BUA, but this may well reflect similar long-term disease activity in the hands and feet in this group of patients.
The established methods of assessing BMD, namely DXA of hip and spine, were included to allow comparison with pQCT and ultrasound within the same population. A significant reduction in FN BMD of 12.8% (0.71 ..) and 15.4% (0.93 ..) in the RA and RA + P groups, respectively, with no significant corticosteroid effect is in keeping with most of the present literature [6] [7] [8] 23] . Such reductions are associated with an increased risk of future hip fracture [24] , which has recently been demonstrated in the RA population [25] . Weight and physical activity were important determinants of hip BMD, in keeping with previous work [7, 8] , suggesting that patient mobility helps maintain hip BMD. The 4.5 and 7.9% reductions in LS BMD for the RA and RA + P groups, respectively, failed to reach significance and are smaller than those recorded at the hip, radius and calcaneus. Although our groups were well matched for age, we cannot exclude age [26] and fracture-related spinal osteoarthrosis influencing our spinal BMD results. Interpretation of our LS results in the light of previous work has to be cautious because of differences in measurement techniques, study populations and dose of corticosteroid. In those studies which examined postmenopausal females, Hall et al. [8] studied larger numbers and found a larger and significant difference of 7.5% between control and non-steroid-treated RA groups. Although a significant difference of 6.5% was found between steroid-and non-steroid-treated RA groups, the difference was smaller (4.3%), and non-significant when a subgroup with a lower cumulative dose of corticosteroid was examined. Verstraeten et al. [3] studied the effect of higher dose prednisolone in females with much longer disease duration than their non-steroid-treated counterparts. Also, rather unusually, lumbar spine BMD was much higher in the non-steroid RA group compared to the control group, suggesting that either the RA or control group was non-representative. Using QCT, Laan et al. [27] found a reduction of 34.7% in LS trabecular BMD in a low-dose-steroid-treated RA group compared to a non-steroid-treated group, which is much greater than that found in our study. However, QCT measures purely trabecular bone, whereas DXA measures a composite of cortical and trabecular bone, and as such, the techniques are clearly not comparable. In patients with RA, one would not expect differences in radial trabecular BMD (as measured by pQCT) to be comparable to differences in spinal trabecular BMD (as measured by QCT), as the spine is far removed from the periarticular inflammatory process which profoundly influences radial trabecular BMD. Also, there is poor correlation between radial and axial BMD in the general population [28] . Others have examined populations which differed in gender and menopausal status [6, 7, 23, 29] , or studied the effect of higher dose corticosteroid [3, 7, 8, 23] which makes direct comparison with our results difficult.
The numbers of patients in this study are relatively small, but there is 80% power at the 5% level to detect differences of at least 75% of the .. of DXA, pQCT and ultrasound measurements. This is sufficient to detect significant changes at the hip, radius and calcaneus, but not at the LS. At the latter site, the minimal difference detectable is 0.14 g/cm 2 (15.7%), a value which exceeds previous significant differences in larger studies.
This study has highlighted important changes in appendicular bone mass in RA. There is now good evidence that bone loss occurs early in RA at the radius [17, 18] , hip and spine [4] , with axial bone loss being related to disease and physical activity [4] . Recently, there has been interest expressed in measuring appendicular BMD as a method of monitoring disease activity in RA [1, 30] . pQCT and calcaneal ultrasound, by quantifying trabecular bone adjacent to the carpus and ankle, respectively, offer novel and unique opportunities to study the effect of RA on periarticular bone, and may be valuable methods of monitoring the response to treatments such as DMARDs and corticosteroid. Further work is necessary to examine the clinical use of pQCT and ultrasound in RA.
